(Page 2 of 2)
In this case, they hope to combine the Dicerna molecules with Archemix’s “aptamers”—short synthetic molecules designed to bind very specifically and tightly to certain protein targets.
“This provides a double-punch with one molecule,” says Jim Jenson, Dicerna’s CEO. “This deal is important to Dicerna and to the RNAi field. This will change the game.”
There isn’t any proof yet such drugs will work in people, so these treatments have a long way to go and a lot of high hurdles to clear. Dicerna is also hedging its bets with a number of partners who bring expertise with antibody fragments and peptides, which also might be used to soup up its RNAi drugs. Dicerna already has established a couple of research collaborations (which it hasn’t disclosed) over the past six months, and has “several more discussions underway” that it hopes will lead to a partnership with a Big Pharma company this year, Jenson says.
“This is an area of great interest in the Big Pharma world,” Jenson says.
Archemix, for its part, gets to align itself with a glamorous niche within biotech and keep itself busy as an independent company, a little more than six months after it got dumped at the altar by Lexington, MA-based NitroMed, which was looking to merge. Two months ago, Archemix named Kenneth Bate, the former NitroMed CEO, as its new top executive. This is the first significant R&D deal at Archemix since he came on board.
“This collaboration showcases how our proprietary aptamer technology can be used in conjunction with other therapeutic modalities and we look forward to beginning this exciting work with Dicerna,” Bate said in a statement.
Dicerna wasn’t about to say when it will enter clinical trials with one of these new RNAi-aptamer drugs, although it is most interested in treatments for cancer and metabolic diseases like diabetes, Jenson says. Dicerna, which closed the last bit of its $21.4 million Series A venture round last July—right before the economy tanked—is still “doing well” with its cash balance, Jenson says. But even so, pushing new drugs through development will take more money. Dicerna plans to start raising more money before the end of this year, Jenson says.